(MENAFN- GlobeNewsWire - Nasdaq) Rising Chronic Disease Burden, Biosimilar Insulin Adoption, and Smart Connected Pen Technologies Drive Sustained Market Expansion.Austin, United States, March 12, 2026 (GLOBE NEWSWIRE) -- As per SNS Insider Research, The Injection Pen Market size was valued at USD 46.68 Billion in 2025 and is projected to reach USD 95.06 Billion by 2035, growing at a CAGR of 7.37% during 2026–2035. Due to a fast rise in the global population with Type 2 diabetes and a surge of novel biologic and biosimilar treatments that require a dependable subcutaneous delivery system, the market is expanding exponentially.
Market Size and Forecast:
Market Size in 2025: USD 46.68 Billion Market Size by 2035: USD 95.06 Billion CAGR: 7.37% during 2026–2035 Base Year: 2025 Forecast Period: 2026–2035 Historical Data: 2022–2024
Get a Sample Report of Injection Pen Market:
The U.S. Injection Pen Market has been valued at USD 29.76 Billion in 2025 and is expected to reach USD 60.61 Billion by 2035, growing at an estimated CAGR of 7.35% from 2026 to 2035. The prevalence of diabetes and other chronic diseases is rising, self-injection drug delivery devices are becoming more popular, biologic therapies are being used more frequently, and smart and connected injection pen technologies are continuously improving. These factors are driving the growth of the U.S. injection pen market.
Increasing Prevalence of Diabetes is Boosting the Market Expansion Globally
According to the IDF, about 500 million persons worldwide have diabetes, and the majority of injection pen users are those who need insulin. The addressable population continues to grow as incidence rises in sub-Saharan Africa and South and Southeast Asia. In addition to diabetes, national healthcare programs in the United States, the United Kingdom, Germany, and Japan have tightened treatment recommendations for growth abnormalities and osteoporosis, directing more patients toward injectable medication. Because of this, the pen category has seen an increase in prescription volume that did not exist ten years ago.
Major Players Listed in this Report are:
Novo Nordisk A/S Sanofi S.A. Eli Lilly and Company Becton, Dickinson and Company Ypsomed AG Owen Mumford Ltd. Gerresheimer AG SHL Medical AG Haselmeier GmbH Nemera Development S.A. Terumo Corporation Jiangsu Delfu Medical Device Co., Ltd. Jiangsu Wanhai Medical Devices Co., Ltd. Biocorp Production S.A. Phillips-Medisize West Pharmaceutical Services, Inc. AptarGroup, Inc. Kaleo, Inc. Consort Medical Plc Bespak
Segmentation Analysis:
By Product
In 2025, Disposable dominated with 68% share as they ship prefilled, require no patient assembly, and eliminate cross-contamination risk between injections. Reusable fastest growing segment during 2026-2035 as they have a loyal following among patients who inject daily over many years and want to reduce both costs and plastic waste.
By Application
In 2025, Diabetes dominated with 72% share due to the combination of insulin-dependent Type 1 patients, the large and growing pool of Type 2 patients moving to injectable therapy, and the GLP-1 class for weight management. Osteoporosis fastest growing segment during 2026-2035 as diagnosis rates are improving as bone density screening becomes more routine.
By End-Use
In 2025, Hospital dominated with 60% share as most patients get their first injection pen a physician or diabetes nurse demonstrates the device. Home Care Settings fastest growing segment during 2026-2035 as it is the place where the volume of injections actually happens.
Need Any Customization Research on Injection Pen Market, Enquire Now:
Injection Pen Market Segmentation
By Product
By Application
Diabetes Anaphylaxis Osteoporosis Growth Hormone Deficiency Arthritis Others
By End-Use
Hospital Clinics Home Care Settings
Regional Insights:
North America is the largest single market, and the U.S. drives most of that. Insulin prices have been a political flashpoint for years, and the Inflation Reduction Act's cap on Medicare insulin cost-sharing has pushed more patients into therapy which feeds pen demand. The U.S. also has the most advanced commercial infrastructure for connected pen devices and digital diabetes management.
The fastest-growing region is Asia-Pacific. The number of people with diabetes in China and India is higher than in most other nations, and both governments have designated insulin access as a public health priority. With competitive local pen platforms, Japan boasts a robust domestic medical device industry. Due to the high cost of pens, a significant portion of the diabetic population in lower-income APAC countries continues to utilize syringes.
Recent Developments:
In 2024, Novo Nordisk rolled out updated delivery devices for its semaglutide and next-generation insulin portfolio, with particular attention to dose accuracy at the lower end of the dosing range. In 2024, Sanofi made incremental updates to the SoloStar platform to maintain compatibility as it extended its biosimilar insulin partnerships.
Exclusive Sections of the Report (The USPs):
INJECTION PEN ADOPTION RATE – helps you understand the shift of diabetes patients from traditional vial-and-syringe methods toward pen-based drug delivery systems, highlighting the growing preference for convenient and patient-friendly injection solutions. DEVICE TECHNOLOGY & SMART CONNECTIVITY TRENDS – helps you evaluate the transition from conventional injection pens to advanced devices with features such as smart connectivity, dose memory, mobile health integration, and ergonomic patient-centric designs. DISPOSABLE VS. REUSABLE DEVICE SHARE – helps you identify demand patterns between disposable and reusable injection pens, providing insights into device lifecycle trends, replacement cycles, and long-term cost implications for healthcare providers and patients. HEALTHCARE UTILIZATION & PATIENT SPENDING ANALYSIS – helps you understand the average annual spending on injection pen devices and related consumables, along with the percentage of insulin therapies delivered through pen injectors compared to traditional syringe methods. REGIONAL ADOPTION & DISEASE PREVALENCE IMPACT – helps you assess how diabetes prevalence and healthcare infrastructure across regions such as North America, Europe, and Asia-Pacific influence the demand and distribution of injection pen drug delivery devices.
Injection Pen Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 46.68 Billion |
| Market Size by 2035 | USD 95.06 Billion |
| CAGR | CAGR of 7.37% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Purchase Single User PDF of Injection Pen Market Report (20% Discount):
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Market Overview
4. Statistical Insights & Trends Reporting
5. Injection Pen Market Segmental Analysis & Forecast, By Product
6. Injection Pen Market Segmental Analysis & Forecast, By Application
7. Injection Pen Market Segmental Analysis & Forecast, By End-Use
8. Injection Pen Market Segmental Analysis & Forecast, By Region
9. Competitive Landscape
10. Analyst Recommendations
11. Assumptions
12. Disclaimer
13. Appendix
Access Complete Report Details of Injection Pen Market Analysis & Outlook:
[For more information or need any customization research mail us at...]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email:...
![]()
MENAFN12032026004107003653ID1110851783
Comments
No comment